WEBULL

Cannara Biotech (TSX:LOVE) Stock Faces Margin Decline As Net Profit Margin Falls To 9.3%

Simply Wall St · 16h ago

Cannara Biotech (TSX:LOVE) has reported Q3 2026 revenue of C$31.8 million, with basic EPS of C$0.049 and net income excluding extra items of C$4.8 million, setting a clear marker for this earnings season. The company has seen quarterly revenue move from C$27.1 million in Q2 2026 to C$31.8 million in Q3 2026, while basic EPS shifted from C$0.017 in Q2 to C$0.049 in Q3, giving investors fresh numbers to set against the recent year of growth and margin compression. With trailing 12 month revenue at C$117.3 million and EPS of C$0.114, the latest print puts the spotlight squarely on how Cannara Biotech is balancing growth with pressure on margins.

See our full analysis for Cannara Biotech.

With the Q3 scorecard set, the next step is to see how these results line up against the widely shared narratives around Cannara Biotech's growth profile, risks, and margin trajectory, and where those stories might need updating.

See what the community is saying about Cannara Biotech

TSX:LOVE Revenue & Expenses Breakdown as at Jul 2026
TSX:LOVE Revenue & Expenses Breakdown as at Jul 2026

TTM profit of C$10.9 million vs tighter 9.3% margin

  • Over the trailing 12 months, Cannara Biotech generated C$117.3 million in revenue and C$10.9 million in net income excluding extra items, which works out to a 9.3% net margin compared with 15.2% a year earlier.
  • Critics highlight that the bearish concern around profitability is grounded in this margin shift, yet the earnings base remains positive:
    • Operating profit over the latest reported quarters stayed positive, with quarterly net income excluding extra items between C$1.0 million and C$4.8 million, so the business is still generating profit even with a lower margin percentage.
    • Bears worry that higher sales and marketing and G&A costs, each around 10% of sales according to the risk discussion, could keep margins closer to the current 9.3% level instead of moving back toward the earlier 15.2% profile.

Revenue growing around 20.8% with capacity ramping

  • The analysis data points to revenue growing about 20.8% per year over the last 12 months, with quarterly revenue in the recent period ranging from C$26.5 million to C$31.8 million as Cannara Biotech brings more capacity online.
  • Consensus narrative leans bullish on this growth path, and the capacity story helps explain why:
    • Cannara Biotech is expanding cultivation and processing at Valleyfield and preparing 3 additional grow rooms, each cited as having potential to generate over C$10 million in annual net revenue, which lines up with the current quarterly revenue range.
    • The company has grown national retail market share to 4.4% in what is described as a flat Canadian retail market, and holds roughly 14.3% share in Quebec, suggesting volume gains are coming from share wins rather than broader market growth.

Bulls point to revenue growth near 20.8% and new grow rooms each targeting over C$10 million in annual net revenue as reasons the story could still be in early innings, even with current margins at 9.3%.

🐂 Cannara Biotech Bull Case

P/E of 17.5x and DCF fair value of C$24.02 vs C$1.92 price

  • The stock trades on a trailing P/E of 17.5x, below both peers at 24.9x and the industry at 18.8x, while the provided DCF fair value of C$24.02 sits far above the current C$1.92 share price.
  • Bears counter that valuation signals need to be read alongside the margin trend and capacity risks:
    • The risk summary flags that net margin moved from 15.2% to 9.3%, which means the lower P/E is being applied to a smaller profit slice on C$117.3 million of trailing revenue.
    • Concerns about a flat Canadian retail market and C$48.6 million of inventory, together with C$89.7 million invested in property, plant and equipment, feed a bearish view that excess capacity and price compression could limit how much of the DCF fair value can be realized.

Skeptics argue that a 17.5x P/E and a DCF fair value of C$24.02 only tell part of the story when margins are at 9.3% and the current price is C$1.92, so they focus heavily on whether the C$117.3 million revenue base can support higher quality earnings over time.

🐻 Cannara Biotech Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cannara Biotech on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of bullish and bearish arguments around Cannara Biotech, it makes sense to review the full picture yourself and move promptly while the latest earnings are still fresh, including weighing the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Cannara Biotech is growing revenue but faces a tighter 9.3% net margin, higher sales and marketing and G&A costs, and concerns around excess capacity and inventory.

If you are uneasy about these margin and capacity pressures and want ideas with stronger financial cushions, check out the solid balance sheet and fundamentals stocks screener (10 results) to move quickly while opportunities are still overlooked.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.